- The newly created pharmaceutical company will expand treatment options with biosimilars, starting with oncology, followed by new launches and commercial agreements.
- Organon and BioSim intend to value this segment of drugs in a synergistic way.
Organon has announced its incorporation as a member of the General Assembly of the Spanish Association of Biosimilar Medicines, biosim. This represents another milestone for both entities. Organon, a company aimed at improving the comprehensive health of women, which has original medicines and biosimilar products in its portfolio, was born as an independent company in mid-2021 and a few months later it has made the decision to join the Association. For BioSim, for its part, it means the consolidation of the entity as a benchmark for laboratories that research, develop, produce and/or market biosimilar medicines, with common principles and objectives. Thus, through different initiatives, both organizations will continue to promote the use of biosimilar medicines and transfer their value to the administration, health professionals, patients and the general public.
In the words of Joaquín Rodrigo, president of BioSim “We appreciate Organon's firm commitment to BioSim. Its incorporation is, without a doubt, synonymous with commitment to the values of the Association and to these medicines. We are fully sure that they will provide an innovative vision, posing challenges that encourage the Association to continue improving and increasing its full potential. New voices and different approaches in our General Assembly will generate enriching debates that will lead to more holistic projects”.
For his part, Juan Vera, CEO of Organon in Spain points out that: "BioSim plays a fundamental role in the promotion and knowledge of biosimilar medicines in Spain. At our company we believe in the importance of this type of treatment, which facilitates access to innovation for patients and contributes to the sustainability of the health system. Our biosimilar portfolio is currently focused on cancer treatments, but we want to expand it so that we can also offer innovative and affordable medicines for other diseases in the coming years.”
About Organon
Organon (NYSE: OGN) is a global health company, formed from the spin-off of MSD (known as Merck in the United States and Canada), to focus on improving the health of women throughout their lives. A company that is here for women's health, with a portfolio of more than 60 medicines and products in a variety of therapeutic areas, led by the reproductive health unit, together with a rapidly expanding biosimilars unit and an established franchise of original brands in key therapeutic areas of women's health such as Cardiovascular, Respiratory, Pain or Mental Health. Likewise, Organon seeks collaboration possibilities with innovative biopharmaceuticals for the commercialization of its products, contributing its size and presence in fast-growing international markets.
For more information about the Company: www.organon.com/spain
